- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03511027
Medication Dispenser to Improve Care at Home for the Elderly
Next-generation Medication Dispenser to Improve Care at Home for Community-dwelling Elderly
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Given the risks associated with poor adherence and the apparent contribution of good adherence to reducing hospitalizations and emergency department (ED) visits, interventions for promoting good adherence should be pursued. To this end, a number of devices have been developed to promote medication adherence, though with limited success due to reliability, cost, etc. The purpose of this study is to investigate the efficacy of the Karie Automated Medication Delivery Device in enhancing medication adherence among a group of community-dwelling patients immediately following discharge from inpatient rehabilitation.
This study will utilize a multi-site randomized controlled trial design. One week prior to discharge from inpatient rehab, consenting patients will be randomly assigned to receive medication self-management education only (SME) or medication self-management education + Karie (SME+K). Both sites (West Park Healthcare Centre, and CapitalCare) will recruit 150 participants for the study. At each site, 75 patients will be in the intervention group (SME + Karie) and 75 will be in the control group (SME only).
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Need to manage medications independently at home
- Stabilized on medication, as per pharmacist/physician discretion; and
- Mild-moderate cognitive/physical impairments, as per OT assessment
- Montreal Cognitive Assessment (MoCA) score not less than 16
- English speaking
Exclusion Criteria:
- Absent from community for more than one month during study
- Inability to access study site pharmacy following discharge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention (SME + Karie Device)
Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge.
In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist.
The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
|
For the duration of the study, participants will use the Karie device to promote medication adherence.
The Karie device prompts users to take their medication in the right amount at the right time.
|
Active Comparator: Control (SME only)
West Park has a "Self-Medication Education Program" policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay.
Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment).
During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge.
Participants in the SME group will fill prescriptions as usual for the duration of study.
|
At discharge, participants will be provided with self-medication education.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Medication Adherence
Time Frame: Baseline (Time 0 Months), 3-months post-baseline(Time 3 Months), 6 months post-baseline (Time 6 Months)
|
The Medication Adherence Questionnaire (MAQ) and medication 7 day recall will measure participants adherence to their medications over time.Both of these measures will be taken at the same time-points throughout the study.
|
Baseline (Time 0 Months), 3-months post-baseline(Time 3 Months), 6 months post-baseline (Time 6 Months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beliefs about medication
Time Frame: Baseline (Time 0M)
|
The Beliefs About Medication questionnaire, assesses participants cognitive representations of medication.
|
Baseline (Time 0M)
|
Change in Self-Medication Behaviours
Time Frame: Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
The investigators will use the Self-Efficacy for Appropriate Medication Scale (SEAMS) to determine participants behaviours and attitudes about self-medication
|
Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
Change in Quality of Life
Time Frame: Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
The investigators will use the EQ-5D to measure changes in quality of life throughout the study.
|
Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
Economic Analysis
Time Frame: 3 months post-baseline (Time 3M), 6 months post-baseline (Time 6M)
|
To determine the affect that the Karie device has on economic indicators, the investigators will be observing staffing hours (OT, Pharmacist), medication costs, and medication wastage.
This will be documented by staff and will be self-reported.
|
3 months post-baseline (Time 3M), 6 months post-baseline (Time 6M)
|
Change in Healthcare Consumption
Time Frame: Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
To determine any changes in healthcare consumption, the investigators will be observing the number of hospitalizations, visits to the GP, and visits to ER for all causes in all of the participants.
|
Baseline (Time 0M), 3-months post-baseline(Time 3M), 6 months post-baseline (Time 6M)
|
Sociodemographic Factors
Time Frame: Baseline (Time 0M)
|
The investigators will be collecting sociodemographic factors such as: Age, Gender, Education, Income, Postal Code.
|
Baseline (Time 0M)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tim Pauley, MSc, West Park Healthcare Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I2P2: AceAge
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Impairment
-
Stanford UniversityRecruitingMild Cognitive Impairment | Subjective Cognitive ImpairmentUnited States
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
Fondazione Don Carlo Gnocchi OnlusUniversity of Florence; Consorzio di Bioingeneria e Informatica Medica; Gutenberg...CompletedCognitive Dysfunction | Mild Cognitive Impairment | Vascular Cognitive ImpairmentItaly
-
University of California, Los AngelesCompletedMild Cognitive Impairment (MCI) | Age-associated Cognitive ImpairmentUnited States
-
Universidad de ZaragozaNot yet recruitingMild Cognitive Impairment | Randomized Controlled Trial | Subjective Cognitive Impairment
-
Region SkaneLund University; Berry LabCompletedMemory Impairment | Cognitive Impairment, MildSweden
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
University of HawaiiRecruitingMild Cognitive Impairment | Subjective Cognitive ImpairmentUnited States
-
Dr. Frances ChungRecruitingCognitive Impairment (CI)Canada
-
Wake Forest University Health SciencesActive, not recruitingCognitive Impairment | Mild Cognitive ImpairmentUnited States
Clinical Trials on SME + Karie Device
-
Kessler FoundationNational Institute on Disability, Independent Living, and Rehabilitation...RecruitingCognitive Impairment | Traumatic Brain InjuryUnited States
-
The University of Hong KongTung Wah Group of HospitalsCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingSick-listed Employees
-
The University of Hong KongThe Hong Kong Council of Social ServiceCompleted
-
The University of Hong KongThe Hong Kong Council of Social ServiceCompleted
-
Kent State UniversityUniversity of Pennsylvania; Case Western Reserve UniversityUnknown
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
Cala Health, Inc.Not yet recruiting
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg